AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9040281 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 12
Study 9040281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 12
Study 8201149 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home geriatric assessments with follow-up visits by trained volunteers
Number of subjects: 254
Study 8201149 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home geriatric assessments
Number of subjects: 254
Study 8201149 — intervention group
Group type: COMPARATOR
Intervention: Control group (telephone interviews)
Number of subjects: 254
Study 3653082 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium 6-8 micrograms kg-1
Number of subjects: 6
Study 3653082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30939096 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (80 mg/m2) with trastuzumab for 12 weeks, followed by trastuzumab for 9 months
Number of subjects: 410
Study 30939096 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50 analysis
Number of subjects: 410
Study 30939096 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping
Number of subjects: 410
Study 30422235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (120 mg subcutaneously once every 4 weeks) in addition to standard care (n=153)
Number of subjects: 309
Study 30422235 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (target blood pressure <140/90 mm Hg; n=152)
Number of subjects: 309
Study 30422235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide
Number of subjects: 309
Study 30422235 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 309
Study 26987626 — intervention group
Group type: EXPERIMENTAL
Intervention: β2‐1 Fructan supplementation (3×5 g/d)
Number of subjects: 30
Study 26987626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 30
Study 24206841 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol administration for fever (≥37·5°C)
Number of subjects: 718
Study 24206841 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin administration for hyperglycemia (>11 mmol/L)
Number of subjects: 718
Study 24206841 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallow assessment by a speech pathologist
Number of subjects: 718
Study 24206841 — intervention group
Group type: COMPARATOR
Intervention: Swallow screening by a nonspeech pathologist
Number of subjects: 718
Study 24206841 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassessment by a speech pathologist after passing a swallow screen
Number of subjects: 718
Study 24206841 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmation of safe swallowing after reassessment
Number of subjects: 718
Study 22502814 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Level Helium Neon (He‐Ne) Laser therapy (λ=632.8 nm, P=24 mW, ED=3.5 J/cm(2))
Number of subjects: 121
Study 22502814 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Level Helium Neon (He‐Ne) Laser therapy
Number of subjects: 121
Study 22502814 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 121
Study 19071225 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 microg MDI‐TRE
Number of subjects: 39
Study 19071225 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 microg MDI‐TRE
Number of subjects: 39
Study 19071225 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 microg MDI‐TRE
Number of subjects: 39
Study 19071225 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 39
Study 17449572 — intervention group
Group type: EXPERIMENTAL
Intervention: SUC (sucrose)
Number of subjects: 10
Study 17449572 — intervention group
Group type: COMPARATOR
Intervention: WAT (water)
Number of subjects: 10
Study 17449572 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO (isomaltulose)
Number of subjects: 10
Study 15946379 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain group
Number of subjects: 94
Study 15946379 — intervention group
Group type: COMPARATOR
Intervention: Non-drain group
Number of subjects: 94
Study 11835024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (bolus of 0.1 mg/kg followed by an infusion of 0.25 mg/kg/h)
Number of subjects: 133
Study 11835024 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (bolus of 70 U/kg followed by an infusion of 15 U/kg/h)
Number of subjects: 133
Study 11835024 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 133
Study 11835024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 133
Study 11198951 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose supplements of nutrients (specific nutrients not detailed)
Number of subjects: 0
Study 11198951 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study 11198951 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium
Number of subjects: 0
Study 11198951 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets rich in fruits and vegetables
Number of subjects: 0
Study 8834126 — intervention group
Group type: COMPARATOR
Intervention: Diabetic nephropathy patients
Number of subjects: 56
Study 2036692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% and fentanyl 4 micrograms.ml‐1 (Group I)
Number of subjects: 75
Study 2036692 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (Group II)
Number of subjects: 75
Study 2036692 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125% (Group III)
Number of subjects: 75
Study 2036692 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% and fentanyl (Group I)
Number of subjects: 75
Study 7236478 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 131
Study 7236478 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin + enflurane
Number of subjects: 131
Study 7236478 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone + halothane
Number of subjects: 131
Study 7236478 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 131
Study 31122894 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil-guided therapy (37.5 mg of oral prednisolone daily for up to 4 days based on eosinophil count)
Number of subjects: 318
Study 31122894 — intervention group
Group type: COMPARATOR
Intervention: Control group (37.5 mg of oral prednisolone daily for 4 days)
Number of subjects: 318
Study 31122894 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophil-guided therapy
Number of subjects: 318
Study 31122894 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 318
Study 26218727 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC‐20L (Juvéderm Voluma XC) injected in zygomaticomalar subregion
Number of subjects: 235
Study 26218727 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC‐20L (Juvéderm Voluma XC) injected in anteromedial cheek subregion
Number of subjects: 235
Study 26218727 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC‐20L (Juvéderm Voluma XC) injected in submalar subregion
Number of subjects: 235
Study 26218727 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC‐20L (Juvéderm Voluma XC) with higher injection volumes
Number of subjects: 235
Study 26218727 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC‐20L (Juvéderm Voluma XC) with median injection volume of ≈2.0 mL
Number of subjects: 235
Study 26218727 — intervention group
Group type: EXPERIMENTAL
Intervention: VYC‐20L (Juvéderm Voluma XC)
Number of subjects: 235
Study 23967286 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g/d polyphenol soy protein complex (PSPC) for 17 days
Number of subjects: 35
Study 23967286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 21844821 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (VAL)
Number of subjects: 48
Study 21844821 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 48
Study 19625744 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (1 mU.kg(‐1).min(‐1)) and dextrose to maintain euglycemia
Number of subjects: 35
Study 19625744 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (150 microg/h)
Number of subjects: 35
Study 19625744 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin, dextrose, and octreotide
Number of subjects: 35
Study 19625744 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemia with euglycemia
Number of subjects: 35
Study 19625744 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 35
Study 17355547 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy according to classical Chinese Medicine (Heidelberg Model)
Number of subjects: 47
Study 17355547 — intervention group
Group type: COMPARATOR
Intervention: Best medical care (control group)
Number of subjects: 47
Study 17355547 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy
Number of subjects: 47
Study 15128959 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual placement and support services
Number of subjects: 0
Study 15128959 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace fundamental skills module (supplementing individual placement and support)
Number of subjects: 0
Study 15128959 — intervention group
Group type: COMPARATOR
Intervention: Traditional types of vocational rehabilitation
Number of subjects: 0
Study 11167431 — intervention group
Group type: EXPERIMENTAL
Intervention: Vital capacity breathing with 8% sevoflurane
Number of subjects: 60
Study 11167431 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal breathing with 8% sevoflurane
Number of subjects: 60
Study 11167431 — intervention group
Group type: COMPARATOR
Intervention: Tidal breathing with step-up of sevoflurane
Number of subjects: 60
Study 11229246 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B deoxycholate (ABD), 1 mg/kg day on days 1‐20, infusion completed in 2 hours.
Number of subjects: 130
Study 11229246 — intervention group
Group type: COMPARATOR
Intervention: Escalating dose of ABD (0.05 mg/kg, 0.1 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 1 mg/kg on days 1‐5, then same dosage on alternate days), infusion completed in 6 hours.
Number of subjects: 130
Study 11229246 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 130
Study 11229246 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (newer mode)
Number of subjects: 130
Study 11229246 — intervention group
Group type: COMPARATOR
Intervention: Group A (classical mode)
Number of subjects: 130
Study 7566302 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated powdered charcoal (6 g daily p.o.)
Number of subjects: 23
Study 2231839 — intervention group
Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine and dapsone) administered fortnightly by village health workers (VHWs)
Number of subjects: 1500
Study 688736 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg spironolactone per day (low dose)
Number of subjects: 36
Study 688736 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg spironolactone per day (high dose)
Number of subjects: 36
Study 688736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 30703667 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-session intervention arm
Number of subjects: 788
Study 30703667 — intervention group
Group type: COMPARATOR
Intervention: Measurement-only control arm
Number of subjects: 788
Study 28493744 — intervention group
Group type: COMPARATOR
Intervention: Menthol cigarette use
Number of subjects: 474
Study 28493744 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast NMR
Number of subjects: 474
Study 25833781 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month weight loss intervention
Number of subjects: 24
Study 25833781 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month weight loss intervention
Number of subjects: 24
Study 25833781 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in percentage body fat and plasma glucose concentrations
Number of subjects: 24
Study 25833781 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in dietary measures (vegetable, protein, total caloric intake)
Number of subjects: 24
Study 25833781 — intervention group
Group type: EXPERIMENTAL
Intervention: Intake of fruit
Number of subjects: 24
Study 23158966 — intervention group
Group type: EXPERIMENTAL
Intervention: Real cervical manipulation (RM)
Number of subjects: 64
Study 23158966 — intervention group
Group type: COMPARATOR
Intervention: Sham cervical manipulation (SM)
Number of subjects: 64
Study 23158966 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RM and SM
Number of subjects: 64
Study 21122419 — intervention group
Group type: EXPERIMENTAL
Intervention: NP/GP scheme synchronization chemotherapy combined with (125)I seed implantation brachytherapy
Number of subjects: 76
Study 21122419 — intervention group
Group type: COMPARATOR
Intervention: NP/GP scheme chemotherapy
Number of subjects: 76
Study 19028251 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation
Number of subjects: 10
Study 19028251 — intervention group
Group type: COMPARATOR
Intervention: Manual contact intervention (MCI)
Number of subjects: 10
Study 15717462 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (1 mg x kg(‐1) bolus before incision, followed by continuous infusion of 1 mg x kg(‐1) x hr(‐1) during surgery)
Number of subjects: 16
Study 15717462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ketamine administration)
Number of subjects: 16
Study 12501020 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine and 20‐40 W bicycle exercise (stress study)
Number of subjects: 64
Study 12501020 — intervention group
Group type: COMPARATOR
Intervention: Rest study
Number of subjects: 64
Study 12501020 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight increase
Number of subjects: 64
Study 12501020 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with patient weight
Number of subjects: 64
Study 12501020 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection activity adjustment
Number of subjects: 64
Study 10643362 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprotte G24 needle
Number of subjects: 197
Study 10643362 — intervention group
Group type: COMPARATOR
Intervention: Spinocan G27 needle
Number of subjects: 197
Study 10643362 — intervention group
Group type: COMPARATOR
Intervention: Atraucan G26 needle
Number of subjects: 197
Study 8877156 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cetirizine (15 mg twice daily for 3 days)
Number of subjects: 0
Study 8877156 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone (single dose 10 min prior to allergen challenge)
Number of subjects: 0
Study 8877156 — intervention group
Group type: COMPARATOR
Intervention: Inhaled beclomethasone
Number of subjects: 0
Study 8877156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1846253 — intervention group
Group type: EXPERIMENTAL
Intervention: CsA/P
Number of subjects: 128
Study 1846253 — intervention group
Group type: COMPARATOR
Intervention: CsA/Aza/P
Number of subjects: 128
Study 1846253 — intervention group
Group type: EXPERIMENTAL
Intervention: Aza/P
Number of subjects: 128
Study 6469425 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg/day)
Number of subjects: 57
Study 6469425 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (600 mg/day)
Number of subjects: 57
Study 6469425 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 57
Study 31188064 — intervention group
Group type: EXPERIMENTAL
Intervention: Apparent diffusion coefficient (ADC) values
Number of subjects: 0
Study 31188064 — intervention group
Group type: EXPERIMENTAL
Intervention: ADC ratios
Number of subjects: 0
Study 31188064 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhancement ratios (ERs)
Number of subjects: 0
Study 31188064 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ADC ratio and ER
Number of subjects: 0
Study 30004560 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous balloon kyphoplasty (PKP)
Number of subjects: 161
Study 30004560 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous vertebroplasty (PVP)
Number of subjects: 161
Study 26398965 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading perturbation (known)
Number of subjects: 17
Study 26398965 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloading perturbation (known)
Number of subjects: 17
Study 26398965 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized loading/unloading perturbation (unknown)
Number of subjects: 17
Study 23944632 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 60
Study 23944632 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 60
Study 23944632 — intervention group
Group type: COMPARATOR
Intervention: Statins (Atorvastatin and Rosuvastatin)
Number of subjects: 60
Study 23131370 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage (four one-hour sessions every two weeks)
Number of subjects: 16
Study 23131370 — intervention group
Group type: COMPARATOR
Intervention: Control (no massages during the control period)
Number of subjects: 16
Study 20679528 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (STI571)
Number of subjects: 0
Study 20679528 — intervention group
Group type: COMPARATOR
Intervention: BCR‐ABL transcripts > 10% at 6 months and > 1% at 12 months
Number of subjects: 0
Study 20679528 — intervention group
Group type: COMPARATOR
Intervention: Complete cytogenetic response but not MMR
Number of subjects: 0
Study 20679528 — intervention group
Group type: EXPERIMENTAL
Intervention: Major molecular response (MMR) at 18 months
Number of subjects: 0
Study 17351083 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized tracking training (track group)
Number of subjects: 20
Study 17351083 — intervention group
Group type: COMPARATOR
Intervention: Movement training (move group)
Number of subjects: 20
Study 16461248 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 2 mL tea catechin extract solution (3.7 mg/mL catechins, 43% epigallocatechin gallate) 3 times daily for 7 days
Number of subjects: 72
Study 16461248 — intervention group
Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 72
Study 15247119 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (45 minutes, 5 days per week of moderate intensity sports/recreational exercise)
Number of subjects: 173
Study 15247119 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 173
Study 10716463 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional Coronary Atherectomy (DCA)
Number of subjects: 0
Study 10716463 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Transluminal Coronary Angioplasty (PTCA)
Number of subjects: 0
Study 8958019 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular BMD measurement (DXA)
Number of subjects: 40
Study 8958019 — intervention group
Group type: EXPERIMENTAL
Intervention: Symphysis BMD measurement (DXA)
Number of subjects: 40
Study 8958019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramus BMD measurement (DXA)
Number of subjects: 40
Study 1547962 — intervention group
Group type: EXPERIMENTAL
Intervention: tobramycin (15 mg/ml) in low-molecular-weight hyaluronic acid applied at 1 drop/h
Number of subjects: 26
Study 1547962 — intervention group
Group type: COMPARATOR
Intervention: tobramycin (15 mg/ml) in saline applied at 1 drop/h
Number of subjects: 26
Study 3873582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenated crystalloid solution
Number of subjects: 151
Study 3873582 — intervention group
Group type: COMPARATOR
Intervention: Oxygenated solution
Number of subjects: 151
Study 30612946 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5 mg once daily for 6 months
Number of subjects: 30
Study 30612946 — intervention group
Group type: COMPARATOR
Intervention: Low-dose testosterone (about 1 mg/kg bodyweight) intramuscular injections every 4 weeks for 6 months
Number of subjects: 30
Study 26989837 — intervention group
Group type: EXPERIMENTAL
Intervention: State insurance mandates requiring insurance plans to cover Pap tests
Number of subjects: 600000
Study 26989837 — intervention group
Group type: COMPARATOR
Intervention: No state insurance mandate
Number of subjects: 600000
Study 26537879 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 108
Study 26537879 — intervention group
Group type: COMPARATOR
Intervention: Standard adhesive gauze dressing
Number of subjects: 108
Study 23327869 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide plus oxaliplatin (EO)
Number of subjects: 71
Study 23327869 — intervention group
Group type: COMPARATOR
Intervention: Etoposide plus cisplatin (EP)
Number of subjects: 71
Study 21490523 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia (0.25% levobupivacaine and 30 μg/kg morphine)
Number of subjects: 32
Study 21490523 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral block (0.5% levobupivacaine and 30 μg/kg morphine)
Number of subjects: 32
Study 21490523 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 32
Study 21490523 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral block
Number of subjects: 32
Study 19679747 — intervention group
Group type: EXPERIMENTAL
Intervention: Quercetin supplementation (1 g/day for 7-16 days)
Number of subjects: 30
Study 17343724 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Cardiac Outpatient Telemetry (MCOT)
Number of subjects: 122
Study 15010071 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy patients
Number of subjects: 90
Study 15010071 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy patients with elevated PAI-1
Number of subjects: 90
Study 15010071 — intervention group
Group type: COMPARATOR
Intervention: Control group (orchidectomy only and healthy men)
Number of subjects: 90
Study 11220813 — intervention group
Group type: EXPERIMENTAL
Intervention: Home environmental intervention (5 90-min home visits by occupational therapists)
Number of subjects: 171
Study 11220813 — intervention group
Group type: EXPERIMENTAL
Intervention: Home environmental intervention
Number of subjects: 171
Study 11220813 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 171
Study 9670603 — intervention group
Group type: EXPERIMENTAL
Intervention: CARL therapy program (computerized exposure therapy)
Number of subjects: 9